Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Percy

Showing results (191-200 of 227) with videos related to

Pageof 23
Sort By:
Molecular Cancer Therapeutics|February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Investigational New Drugs|August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumorsAmir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology|September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F Liu, William T Barry, Michael Birrer, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRoisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research StatementEdward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Pageof 23

Showing results (191-200 of 227) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Investigational New Drugs|August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumorsAmir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology|December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survivalOvidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Cancer Chemotherapy and Pharmacology|April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyTiciana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology|September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F Liu, William T Barry, Michael Birrer, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRoisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research StatementEdward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Pageof 23